Pharmacyclics LLC. clinical trials

Acquired by AbbVie, May 26, 2015 · source ↗

The registry lists 54 studies whose lead sponsor is Pharmacyclics LLC.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 10, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 54. List all 54 → · All AbbVie studies →

• Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaCompletedNCT02947347Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03790332Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)CompletedNCT03112174Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01724346Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsCompletedNCT02599324Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)CompletedNCT02959944Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic LeukemiaCompletedNCT02582879

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)CompletedNCT02436668Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT01478581Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted after Pharmacyclics LLC. became part of AbbVie

• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone LymphomaCompletedNCT01980628Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02195869Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaTerminatedNCT02351037Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLLCompletedNCT01722487Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT01325701Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p DeletionCompletedNCT01744691Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLCompletedNCT01217749Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)TerminatedNCT00373204Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00076401Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00100711Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain MetastasesTerminatedNCT00121420Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With GemcitabineCompletedNCT01020006Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedNCT00724984Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Safety of PCI-32765 in Chronic Lymphocytic LeukemiaCompletedNCT01105247Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain MetastasesCompletedNCT00003563Phase 3

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung CancerTerminatedNCT00365183Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedNCT01149668Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedNCT00562224Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer PatientsCompletedNCT00473577Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00102505Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant GliomasCompletedNCT00080054Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00290004Phase 1/2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung CancerCompletedNCT00129844Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie

• Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's LymphomaCompletedNCT00086034Phase 2

  Sponsor listed in the registry: Pharmacyclics LLC. · First submitted before Pharmacyclics LLC. became part of AbbVie